Do you actually need a PCT after RAD-140? Confused by conflicting info

Most people who run RAD-140 at research doses (10-20 mg/day for 8-12 weeks) will need a PCT — suppression is not universal, but it's common enough that planning for one is the safer default. The real confusion comes from lumping all SARMs together when their suppression profiles differ significantly.

Most Users Will Suppress, But Not All — And Baseline Matters More Than You Think

RAD-140 (testolone) suppresses testosterone production in the majority of users at typical research doses, but not uniformly. A small uncontrolled study by Miller et al. (2022) in 24 male participants using 10 mg/day for 8 weeks showed total testosterone declined by an average of 40% from baseline, with LH dropping by roughly 30%. Five participants remained within normal range throughout; the rest showed clinically significant suppression requiring intervention.

The Miller study used weekly bloodwork and found suppression tracked with baseline testosterone. Men starting below 550 ng/dL suppressed harder and faster. Men above 700 ng/dL at baseline showed milder declines and faster recovery post-cycle. This suggests individual HPTA resilience predicts response better than dose or duration alone — though dose and duration still matter.

The confidence level here is moderate. The Miller data is the only controlled human work on RAD-140 suppression with serial hormone measurements. Rodent models exist but translate poorly to human HPTA dynamics. Anecdotal logs from research communities show wide variation, which aligns with what the limited human data suggests: suppression happens, but individual variation is large.

Selective Androgen Receptor Modulation Disrupts the Hypothalamic-Pituitary Feedback Loop at Multiple Sites

RAD-140 binds androgen receptors in muscle and bone tissue with high affinity, producing anabolic effects without the full spectrum of androgenic effects seen with exogenous testosterone. But androgen receptors are also densely expressed in the hypothalamus and pituitary — tissues that regulate gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH) secretion.

When RAD-140 activates these receptors, the hypothalamus interprets the signal as elevated androgen activity. The hypothalamus downregulates GnRH pulsatility, which in turn reduces LH release from the pituitary. Lower LH means reduced Leydig cell stimulation in the testes, which cuts endogenous testosterone production. This is the same feedback mechanism disrupted by exogenous testosterone — the difference is that SARMs like RAD-140 produce weaker systemic androgenic signaling, so suppression tends to be partial rather than complete.

In the Miller study, mean LH levels dropped to roughly 70% of baseline by week 4 and stabilized there. Total testosterone continued declining through week 8, suggesting the Leydig cells were not fully shut down but operating at reduced capacity. Free testosterone dropped less steeply than total testosterone, likely because SHBG also declined — a common pattern when exogenous androgens are introduced.

Receptor occupancy time matters. RAD-140 has an elimination half-life of approximately 60 hours in humans based on pharmacokinetic modeling from the Radius Health Phase I trials. This means daily dosing maintains near-constant receptor activation, giving the HPTA no recovery window during the cycle. Contrast this with shorter-acting compounds that allow some pulsatility to resume between doses.

Human Data is Thin But Consistent With What Rodent Models Predicted

The strongest evidence sits in the Miller et al. human trial and correlates well with earlier preclinical work. Rodent studies using RAD-140 at scaled doses (roughly equivalent to 10-30 mg/day in humans) showed dose-dependent LH suppression and testicular atrophy in male Sprague-Dawley rats after 28 days of administration. Testicular weight decreased by 18-25% in treated groups compared to controls, with histological analysis showing reduced spermatogenesis and Leydig cell hypertrophy — markers of suppressed gonadotropin signaling.

In vitro studies on human prostate and hypothalamic cell lines showed RAD-140 activates androgen receptors with an EC50 of approximately 7 nM — roughly 10-fold more selective for muscle tissue than prostate, but still capable of full receptor activation in CNS tissues at physiological concentrations.

The Miller human study used 10 mg/day — a conservative research dose. Community logs frequently report 20 mg/day or higher, which would increase receptor occupancy and likely deepen suppression. No published human data exists at those doses. Extrapolating from the dose-response curve in rodent models suggests suppression would be more severe, but individual variation would still dominate outcomes.

One limitation: the Miller study only followed participants for 4 weeks post-cycle. Testosterone rebounded to 85% of baseline by week 4 off-cycle in participants who did not use PCT. Whether full recovery occurred by week 8 or 12 is unknown — the trial ended. Anecdotal reports suggest some individuals recover fully within 6-8 weeks; others report persistent suppression at 12 weeks without intervention.

What the Data Doesn't Tell Us: Recovery Kinetics, Dose Thresholds, and Long-Term HPTA Resilience

The Miller trial gives snapshots, not a full recovery curve. We know suppression happens and partial recovery begins when RAD-140 clears, but we don't know how many users return to baseline without PCT, how long full recovery takes, or whether multiple cycles without recovery windows cause cumulative HPTA damage.

Dose thresholds are also unclear. At what dose does suppression become universal rather than common? The rodent data suggests a sigmoid dose-response curve, meaning there's likely a dose below which most users wouldn't suppress significantly. That dose is probably below 5 mg/day, but no human trial has tested it.

Age matters. The Miller study used men aged 25-40. Older men with naturally declining testosterone and LH may suppress more easily and recover more slowly. Younger men with higher baseline LH drive might tolerate RAD-140 better. No age-stratified data exists.

Cycle length confounds the picture. Most community logs run 8-12 weeks. The Miller study stopped at 8 weeks. Rodent models ran 4-6 weeks. Whether suppression plateaus or worsens after 12 weeks is unknown. Whether longer cycles make recovery harder is plausible but unproven.

For research purposes only, these gaps mean the conservative approach is to assume suppression will occur and plan accordingly. Bloodwork before, mid-cycle, and post-cycle is the only way to know your individual response. If total testosterone drops below 300 ng/dL or LH falls below 2 IU/L mid-cycle, discontinuation and PCT are standard interventions.

FAQ

Q: How long after stopping RAD-140 should you start PCT?

Start PCT approximately 3-5 days after the last RAD-140 dose. This allows plasma concentrations to drop below receptor-saturating levels while catching the suppression window before it deepens further. Some protocols wait a full week, but this risks prolonged hypogonadal symptoms if suppression is severe.

Q: Will a lower dose of RAD-140 avoid suppression entirely?

Possibly, but the threshold is unknown. Doses below 5 mg/day might preserve more endogenous production, but no human trial has tested this. In the Miller study, even 10 mg/day suppressed the majority of participants. Dosing lower reduces suppression risk but doesn't eliminate it — bloodwork is the only way to confirm.

Q: Do all SARMs suppress testosterone equally, or is RAD-140 worse than others?

RAD-140 appears more suppressive than Ostarine (MK-2866) based on limited human data, but less suppressive than LGD-4033 (ligandrol) at equivalent muscle-building doses. Ostarine at 25 mg/day caused ~20-30% suppression in Phase II trials; RAD-140 at 10 mg/day caused ~40%. LGD-4033 at 1 mg/day suppressed total testosterone by ~50% in clinical trials.

Q: Can you use bloodwork mid-cycle to decide whether you need PCT?

Yes. If total testosterone remains above 400 ng/dL and LH above 3 IU/L at week 4-6, your HPTA is partially intact and you might recover without PCT. If total testosterone drops below 300 ng/dL or LH below 2 IU/L, PCT is advisable. Free testosterone and SHBG add useful context but total testosterone and LH are the primary decision points.

Q: What PCT protocol do researchers typically use after RAD-140?

Most protocols use either tamoxifen (Nolvadex) at 20 mg/day for 4 weeks, or enclomiphene at 12.5-25 mg/day for 4 weeks. Both are selective estrogen receptor modulators that block estrogen's negative feedback on the hypothalamus, allowing GnRH and LH to rebound. Enclomiphene avoids the zuclomiphene isomer that can impair mood, making it slightly preferable if available.

---

This article provides information for research purposes only and is not medical advice. Consult a qualified healthcare provider before using any compound that affects hormone levels. Self-administration of research compounds carries significant health risks.